Taizhou Baiying Biotechnology
PrivateLast Round
Series B
Sep 2, 2022
Total Funding Raised
$92.05M
Company Overview
Taizhou Baiying Biotechnology operates in Healthcare & Life Sciences and is based in Shanghai, Shanghai. Its latest recorded funding round was a Series B round in September 2022.
Biointron is a biotechnology company specializing in recombinant antibody technology and contract research organization (CRO) services aimed at streamlining the antibody discovery process through advanced expression platforms, sequencing, and labeling tools.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Taizhou Baiying Biotechnology Comparables
Compare Taizhou Baiying Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Creative Biolabs | 85% | |
| Genovac Antibody Discovery | 82% | |
| ProteoGenix | 82% |
For institutional investors. Book with your work email.
Taizhou Baiying Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 2, 2022 | ||||
| Series A | May 24, 2021 | ||||
| Angel | Jul 23, 2018 |
For institutional investors. Book with your work email.
Taizhou Baiying Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jifeng Ventures | Series B |
| Haitong Bank | Series B |
| Joy Capital | Series B |
| Jiangsu Provincial Government Investment Fund | Series B |
| Furong Investment | Series A |
| ALAN Asset Management | Series B |
| Jiangsu Tianyou Investment Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2026
New platform helps drug developers identify manufacturing problems early.
- Dec 17, 2025
Received the 2025 Scientist.com Supplier Performance Recognition Award.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardNov 10, 2026
Biointron receives the EcoVadis Silver Medal from EcoVadis on Oct 26th '26 for continued progress in sustainability management and responsible business practices, advancing from its Bronze Medal recognition in 2025.
- attends_eventOct 2, 2026
Biointron hosted Antibodies After Hours: Antibodies Meet AI on Oct 2nd '26 in Massachusetts, bringing together scientists and industry professionals for scientific discussions, networking, dinner, and a raffle.
For institutional investors. Book with your work email.
Taizhou Baiying Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Taizhou Baiying Biotechnology's valuation, stock price, and market status.
Is Taizhou Baiying Biotechnology a public or private company?
Taizhou Baiying Biotechnology is a private company.
What is the current stock price of Taizhou Baiying Biotechnology?
Taizhou Baiying Biotechnology is a private company, so its shares have no public market price. Caplight tracks Taizhou Baiying Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Taizhou Baiying Biotechnology worth (valuation)?
Valuation information for Taizhou Baiying Biotechnology is not publicly available.
Can I buy Taizhou Baiying Biotechnology stock?
Taizhou Baiying Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Taizhou Baiying Biotechnology's last funding round?
Taizhou Baiying Biotechnology's most recent funding round was Series B on September 2, 2022.
Who are the main investors in Taizhou Baiying Biotechnology?
Key investors in Taizhou Baiying Biotechnology include Jifeng Ventures, Haitong Bank, CoStone Capital.
Will Taizhou Baiying Biotechnology IPO soon?
No public IPO plans have been announced for Taizhou Baiying Biotechnology.
How can I track Taizhou Baiying Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Taizhou Baiying Biotechnology's shares on secondary markets.